THE NOMINATION COMMITTEE’S PROPOSALS TO THE ANNUAL GENERAL MEETING IN KARO BIO AB (PUBL)

STOCKHOLM, 23 April 2015 – The Nomination Committee of Karo Bio AB (publ) has
informed the company of its proposals to the annual general meeting 2015.
Prior to the annual general meeting 2015, the Nomination Committee has consisted
of Anders Lönner (chairman), chairman of the board, representing own holdings,
Göran Wessman, representing own holdings (Protem Wessman AB), Johan Paulsson,
representing own holdings (JPMP i Visby AB), Leif Edlund, representing Johan
Edlund and Per-Anders Johansson, representing own holdings (Nomic AB). Anders
Lönner has been elected chairman of the Nomination Committee.

The nomination committee proposes re-election of the board members Anders
Lönner, Thomas Hedner, Göran Wessman, Per-Anders Johansson and new election of
Jean Lycke. Sibylle Lenz and Christer Fåhraeus have declined re-election. Anders
Lönner is proposed to be elected chairman of the board.

Jean Lycke (born 1964), has great experience of business development within the
pharmaceutical industry. Jean Lycke is, among other things, chairman of the
board of Tanomed AB, board member and managing director of Emerentia Gruppen AB,
board member of BioResonator Good Eye AB and Santax Nordic A/S. Jean Lycke holds
presently no shares in the company.

The Nomination Committee is of the opinion that the remuneration to the board
should remain unchanged and be paid by SEK 420,000 to the chairman and SEK
150,000 to each of the other directors.

The Nomination Committee further proposes re-election of the accounting firm
PricewaterhouseCoopers AB and that remuneration to the auditor be paid as per
approved invoice.

Advokat Madeleine Rydberger is proposed to be chairman of the meeting.

The Nomination Committee’s reasoned statement on its proposals to the annual
general meeting will be published on the company’s website as soon as it is
received by the company.

For further information, please contact:
Henrik Palm, CFO, email henrik.palm@karobio.se, telephone +46 70 540 4014

About Karo Bio
Karo Bio is a development company focused on broadening its operations to
include projects and products closer to market. Karo Bio has several projects
approaching clinical phase. Karo Bio is based in Huddinge, Sweden and is listed
on Nasdaq Stockholm.

Karo Bio publishes this information according to the Swedish Securities Market
Act. The information was submitted for publication on 23 April 2015, at 8.30
a.m. CET.

This press release is also available at www.karobio.se and
www.newsroom.cision.com